Sandrine Malot

Predictive Features of Severe Acquired ADAMTS13 Deficiency in Idiopathic Thrombotic Microangiopathies: The French TMA Reference Center Experience

Paul Coppo, Michaël Schwarzinger, M. Buffet et al. · PLoS ONE · 2010 · 415 citations · Full text

Medicine, Hematology, Internal Medicine +9

Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center

Antoine Froissart, M. Buffet, Agnès Veyradier et al. · Critical Care Medicine · 2011 · 291 citations

Medicine, Hematology, Immunology +13

Severe ADAMTS13 Deficiency in Adult Idiopathic Thrombotic Microangiopathies Defines a Subset of Patients Characterized by Various Autoimmune Manifestations, Lower Platelet Count, and Mild Renal Involvement

Paul Coppo, Djaouïda Bengoufa, Agnès Veyradier et al. · Medicine · 2004 · 198 citations

Life Sciences, Hematology, Pathology +9

A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP

Paul Coppo, Michaël Bubenheim, Élie Azoulay et al. · Blood · 2020 · 185 citations · Full text

Life Sciences, Immunology, Pharmacology +14

Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience

Y. Benhamou, C. Assié, Pierre‐Yves Boëlle et al. · Haematologica · 2012 · 155 citations · Full text

Medicine, Hematology, Internal Medicine +11